[Featured Stock] Boditech Med Diagnoses COVID-19 and Influenza Simultaneously Ahead of Flu Epidemic

[Asia Economy Reporter Hyungsoo Park] Bodytech Med's stock price is soaring. The news that it has developed a multiplex-type test kit (PCR) capable of diagnosing both novel coronavirus infection (COVID-19) and influenza (types A and B) at once appears to have influenced the stock price.

At 9:12 a.m. on the 27th, Bodytech Med was trading at 27,950 KRW, up 24.5% from the previous day.

Bodytech Med introduced that it can determine the presence of COVID-19 and influenza infections with a single specimen collection. The industry anticipates increased confusion after October, the peak season for outbreaks, as flu symptoms are similar to those of COVID-19, leading to a rush in developing multiplex diagnostic kits.

The kit developed by Bodytech Med is produced using a freeze-drying method, allowing for room temperature shipping and storage. Additionally, since reagents are provided in the PCR test container, testing can be conducted simply by adding the sample collected from the patient.

A Bodytech Med official explained, "We have drastically simplified the testing procedure and significantly reduced the possibility of errors caused by the tester."

Bodytech Med is conducting clinical trials and obtaining export approval from the Ministry of Food and Drug Safety. It is also reported that the timing for sales in the U.S. and European markets is being coordinated ahead of exports.

Bodytech Med has been increasing sales by supplying COVID-19 diagnostic kits to 15 countries. In the second quarter, it achieved sales of 31.2 billion KRW and an operating profit of 15 billion KRW. Compared to the previous year, sales increased by 87.7%, and operating profit rose by 451.0%.

This content was produced with the assistance of AI translation services.